Oral Treatment With an Engineered Uricase, ALLN-346, Reduces Hyperuricemia, and Uricosuria in Urate Oxidase-Deficient Mice
Crossref DOI link: https://doi.org/10.3389/fmed.2020.569215
Published Online: 2020-11-24
Update policy: https://doi.org/10.3389/crossmark-policy
Pierzynowska, Kateryna
Deshpande, Aditi
Mosiichuk, Nadiia
Terkeltaub, Robert
Szczurek, Paulina
Salido, Eduardo
Pierzynowski, Stefan
Grujic, Danica
Funding for this research was provided by:
National Institutes of Health
Version of Record valid from 2020-11-24
